BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Australia

Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial

Actinogen Medical Limited (ASX: ACW) is pleased to announce that the first patient has been randomized and treated in the XanaCIDD Phase 2 depression ...

December 15, 2022 | News

Data Shows 50% of New Trials Have Sites in Asia Pacific

According to the new publication titled "State of the Global Biotech Landscape: Where the Opportunities Lie", demand for Asia Pacific trial sites is strong...

December 15, 2022 | News

Griffith joins $280 million partnership to deliver mRNA vaccine outcomes

The $280 million Translational Science Hub will be established under an agreement between Sanofi, Griffith University, the University of Queensland and the...

December 05, 2022 | News

Inventia enters into a distribution agreement for RASTRUM™ with SCRUM Inc in Japan

RASTRUM™, is a game-changing 3D cell culture platform that’s accelerating the quest to cure cancer and debilitating diseases. With applications...

December 05, 2022 | News

Propanc Biopharma Concludes PRP Could Become an Effective Chemosensitizer Agent Against Pancreatic Cancer

Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer tre...

December 02, 2022 | News

Chemotherapy may be completed within 8 days with two doses of Polytaxel, an innovative anticancer drug from South Korea's biotech firm

Polytaxel, a novel pain-free anticancer drug, may not require break periods A new standard of care, more convenient than docetaxel, is suggest...

November 28, 2022 | News

Hugel's 'Letybo' First in Korea to Obtain Marketing Approval from Australia

Obtained marketing approval on the 23rd (local time) from the Therapeutic Goods Administration (TGA) of Australia for the indication of gl...

November 25, 2022 | News

Australian Scientists Honoured with the Grand Hamdan Award

The Award ceremony of the Sheikh Hamdan bin Rashid Al Maktoum Award for Medical Sciences, hosted in Dubai, took place on 23rd of ...

November 25, 2022 | News

Lunit Partners with CARPL.ai to Accelerate AI-Powered Medical Imaging Across Major Overseas Channels

Lunit signed a global distribution agreement to provide its AI-based radiology solutions for clinical use via CARPL.ai's platform The partnership will d...

November 24, 2022 | News

First Patient Dosed in Phase II 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy

TLX101 (4-L-[131I] iodo-phenylalanine, or 131I-IPA) is one of Telix's lead therapeutic clinical programs and has been granted orphan drug designation ...

November 22, 2022 | News

Monash University Implements Antibody Discovery Application by Utilizing the Berkeley Lights Beacon® Platform

The technology is housed in the Monash Antibody Technology Facility (MATF) where researchers not only from Monash University but elsewhere in Victoria...

November 10, 2022 | News

Telix Announces Positive Topline Results of ZIRCON Phase III Kidney Cancer Imaging Study

Summary of Study Outcomes ZIRCON Phase III study of Telix's investigational imaging agent TLX250-CDx in clear cell renal cell carcinoma (ccRCC) has met ...

November 07, 2022 | News

LUMC to Fund New Clinical Trial of Cynata's Cymerus™ MSCs in Kidney Transplantation

Cynata to collaborate with Leiden University Medical Center (LUMC) in the Netherlands, in a new clinical trial in patients who have received a kidne...

November 04, 2022 | News

Australia First in-human use of OncoRes Medical's cancer imaging system successful

OncoRes Medical today announces positive data from the first in-cavity use of its Quantitative Micro-Elastography (QME) Imaging System. The study, titled&n...

November 03, 2022 | News

Stay Connected